MAY-JUN 2014

MedEsthetics—business education for medical practitioners—provides the latest noninvasive cosmetic procedures, treatment trends, product and equipment reviews, legal issues and medical aesthetics industry news.

Issue link:

Contents of this Issue


Page 81 of 86 | MAY/JUNE 2014 77 M e d E s t h e t i c s PUBLISHER/CEO Deborah Carver • VICE PRESIDENT/CFO Mindy Rosiejka • EDITORIAL DIRECTOR Stephanie Yaggy • EDITORIAL EXECUTIVE EDITOR/ASSOCIATE PUBLISHER Inga Hansen • CONTRIBUTING EDITORS Linda W. Lewis, Maryann Hammers ART CREATIVE DIRECTOR • Dawn Cobalt ART DIRECTOR • Melody Ostil PHOTO EDITOR • Armando Sanchez PREPRESS MANAGER • Cam Campanaro DESKTOP SPECIALIST • Sophia Freeman ADVERTISING ASSOCIATE PUBLISHER/ADVERTISING DIRECTOR Lisa Fisco • lfi ACCOUNT EXECUTIVES Diane Jones • Nazli Santana • WEB/MARKETING MARKETING COORDINATOR • Andrew B. Smith WEB ART/UX DIRECTOR • Ryan Boydstun ASSOCIATE WEB EDITOR • Chrisi Talyn Saje CIRCULATION/PRODUCTION CIRCULATION DIRECTOR • Barbara Shepherd PRODUCTION DIRECTOR • Garnet Blair PRODUCTION MANAGER • Madlen Martinez PRODUCTION ASSISTANTS Claudia Marquez, Flora Robinson ADMINISTRATION ACCOUNTING MANAGER • Lourdes R. Nuno ACCOUNTS RECEIVABLE MANAGER Viktoriya Milshteyn ACCOUNTING ASSISTANT • Suzie Chavez SPECIAL PROJECTS MANAGER • Denise Maiman ADMINISTRATIVE ASSISTANT • Dario Dicochea Questions about your subscription? Contact MedEsthetics, Attn: Subscriptions, PO Box 1072, Skokie, IL. 60076-9712; 800.624.4196; Publication Offi ces: MedEsthetics, 7628 Densmore Ave, Van Nuys, CA 91406-2042. For other questions call 818.782.7328 or fax 818.782.7450. The views and opinions printed herein are not to be taken as offi cial expressions of the publishers, unless so stated. The publishers do not warrant, either expressly or by implication, the factual accuracy of the articles herein, nor do they so warrant any views or opinions offered by the authors of said articles. No part of this publication may be reproduced in any form or by any means, including photocopying, or utilized by any information storage and retrieval system without written permission from MedEsthetics. Copyright 2014 by Creative Age. All rights reserved. Aesthetics Surgical said Stuart Raetzman, CEO of Galderma Laboratories, and vice president, Galderma North America. "We hope this cam- paign will encour- age patients suffering with the embarrassing symptoms of rosacea to speak with their doctors about diagnosis, triggers for the facial redness and treatment options. In ad- dition, we want to reach those who don't know why they have red faces and let them know there are treatment options available. An estimated 16 million Americans have rosacea and we hope this eye-catching campaign successfully delivers the message that they can 'right the wrong' of the facial redness associated with rosacea." Consumers can obtain information about the disease and prescription treatment op- tions through the print, digital and broadcast awareness campaign. The company has also launched a website,, in conjunction with the campaign. "The skin conditions treated by Galderma have strong psychological and social implica- tions in the everyday lives of our consumers. By treating these conditions, we help people preserve, restore and maintain healthy skin and improve their quality of life," said Humberto C. Antunes, CEO & President of Galderma worldwide. NOVAN ANNOUNCES POSITIVE PHASE 2 RESULTS FOR NOVEL ACNE TREATMENT Novan Therapeutics (novantherapeutics. com), a specialty pharmaceutical company focused on medical nitric oxide therapies has announced positive Phase 2 study results of its topical SB204 drug candidate for the treatment of acne vulgaris. The double blind, vehicle-controlled, dose- ranging study included 150 subjects with acne. Subject were randomized evenly to 1% SB204, 4% SB204, or vehicle gel and treated for 12 weeks. SB204 demon- strated good cutaneous tolerability with no reported serious adverse events. Subjects treated with SB204 recognized a benefi t three times faster than the 12-week treatment duration generally needed to see effi cacy with a monotherapy. At four weeks, the 4% dose of SB204 demonstrated a statistically signifi cant reduction in both noninfl ammatory (white heads and black heads) and infl ammatory lesions (larger red bumps and pustules) compared to Vehicle (p ≤ 0.05, intent-to-treat analysis). Statistically signifi cant reductions were also observed in both the primary and secondary endpoints for lesion types at the 12-week time point. "There currently remains a need for new agents to treat the growing number of patients suffering from acne vulgaris. Novan's Phase 2 results of SB204 were very impressive, having demonstrated a rapid and clear dose response in subjects with severe acne," said Hilary Baldwin, MD, dermatolo- gist at SUNY Downstate Medical Center University Hospital of Brooklyn. "In fact, I would typically prescribe an oral antibiotic to the type of patients that were recruited in this study. While systemic antibiotics are an effective treatment option, they may lead to the development of antibiotic resistance. Importantly, with advanced clinical testing, I believe SB204 has the potential to be used as a fi rst-line monotherapy, or in combina- tion with existing drugs, providing an exciting new solution for patients with acne." Exploratory measurements of sebum and the quantitative analysis of the chemical composition of the oils produced by the skin were also collected in a subset of subjects (n=70). The company expects to report additional key fi ndings from this study in the second quarter of 2014. CONTINUING EDUCATION Zein Obagi, MD, of ZO Skin Health will be hosting educational seminars and webinars for physicians and skincare professionals. ZO Skin Health Seminars May 15 – Houston, TX June 12 – Beverly Hills, CA July 17 – Chicago September 18 – Atlanta October 23 – New York City November 20 – Las Vegas ZO Skin Health Webinars June 3 – Rosacea: The Strawberry Fields of Dermatology N e w s E v e n t s M E D 5 - 6 1 4 . i n d d 7 7 News Events MED5-614.indd 77 4 / 1 6 / 1 4 4 : 5 4 P M 4/16/14 4:54 PM

Articles in this issue

Links on this page

Archives of this issue

view archives of Medesthetics - MAY-JUN 2014